vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Skyward Specialty Insurance Group, Inc. (SKWD). Click either name above to swap in a different company.
Skyward Specialty Insurance Group, Inc. is the larger business by last-quarter revenue ($475.9M vs $156.4M, roughly 3.0× BIOCRYST PHARMACEUTICALS INC). On growth, Skyward Specialty Insurance Group, Inc. posted the faster year-over-year revenue change (44.8% vs 7.5%). Over the past eight quarters, Skyward Specialty Insurance Group, Inc.'s revenue compounded faster (30.4% CAGR vs 19.6%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Skyward Specialty Insurance Group, Inc. is a specialty property and casualty insurance provider offering tailored coverage solutions including commercial auto, general liability, professional indemnity, and specialty property policies. It primarily serves small-to-medium enterprises and niche industry segments across the United States, focusing on underwriting complex, hard-to-place risks for underserved client groups.
BCRX vs SKWD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $475.9M |
| Net Profit | — | $49.7M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | 14.9% |
| Net Margin | — | 10.5% |
| Revenue YoY | 7.5% | 44.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $1.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $475.9M | ||
| Q4 25 | $406.6M | $385.6M | ||
| Q3 25 | $159.4M | $382.5M | ||
| Q2 25 | $163.4M | $319.9M | ||
| Q1 25 | $145.5M | $328.5M | ||
| Q4 24 | $131.5M | $304.4M | ||
| Q3 24 | $117.1M | $300.9M | ||
| Q2 24 | $109.3M | $279.9M |
| Q1 26 | — | $49.7M | ||
| Q4 25 | $245.8M | $43.2M | ||
| Q3 25 | $12.9M | $45.9M | ||
| Q2 25 | $5.1M | $38.8M | ||
| Q1 25 | $32.0K | $42.1M | ||
| Q4 24 | $-26.8M | $14.4M | ||
| Q3 24 | $-14.0M | $36.7M | ||
| Q2 24 | $-12.7M | $31.0M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | 14.9% | ||
| Q4 25 | 64.0% | 14.2% | ||
| Q3 25 | 18.6% | 15.8% | ||
| Q2 25 | 18.2% | 15.6% | ||
| Q1 25 | 14.6% | 15.7% | ||
| Q4 24 | -3.4% | 6.1% | ||
| Q3 24 | 6.6% | 15.6% | ||
| Q2 24 | 8.0% | 14.4% |
| Q1 26 | — | 10.5% | ||
| Q4 25 | 60.5% | 11.2% | ||
| Q3 25 | 8.1% | 12.0% | ||
| Q2 25 | 3.1% | 12.1% | ||
| Q1 25 | 0.0% | 12.8% | ||
| Q4 24 | -20.4% | 4.7% | ||
| Q3 24 | -12.0% | 12.2% | ||
| Q2 24 | -11.6% | 11.1% |
| Q1 26 | $0.00 | $1.09 | ||
| Q4 25 | $1.13 | $1.03 | ||
| Q3 25 | $0.06 | $1.10 | ||
| Q2 25 | $0.02 | $0.93 | ||
| Q1 25 | $0.00 | $1.01 | ||
| Q4 24 | $-0.13 | $0.33 | ||
| Q3 24 | $-0.07 | $0.89 | ||
| Q2 24 | $-0.06 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $4.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $1.2B |
| Total Assets | $465.1M | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | $4.1M | ||
| Q4 25 | $274.7M | $168.5M | ||
| Q3 25 | $212.9M | $160.1M | ||
| Q2 25 | $260.0M | $136.6M | ||
| Q1 25 | $295.1M | $112.9M | ||
| Q4 24 | $320.9M | $121.6M | ||
| Q3 24 | $96.8M | $105.6M | ||
| Q2 24 | $78.4M | $73.0M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-119.2M | $1.0B | ||
| Q3 25 | $-387.9M | $961.4M | ||
| Q2 25 | $-421.6M | $899.9M | ||
| Q1 25 | $-451.9M | $850.7M | ||
| Q4 24 | $-475.9M | $794.0M | ||
| Q3 24 | $-468.6M | $797.5M | ||
| Q2 24 | $-475.6M | $723.6M |
| Q1 26 | $465.1M | $6.5B | ||
| Q4 25 | $514.2M | $4.8B | ||
| Q3 25 | $446.4M | $4.6B | ||
| Q2 25 | $457.2M | $4.3B | ||
| Q1 25 | $480.0M | $4.0B | ||
| Q4 24 | $490.4M | $3.7B | ||
| Q3 24 | $491.3M | $3.6B | ||
| Q2 24 | $472.4M | $3.4B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
SKWD
Segment breakdown not available.
